New design, easier handling – URSAPHARM relaunches POSIFORLID® eye mask
Saarbrücken, July 9, 2024. New design, easier handling – URSAPHARM relaunches POSIFORLID® eye mask for the treatment of blepharitis and dysfunction of the glands of the eyelids.
The pharmaceutical manufacturer URSAPHARM has revised the POSIFORLID® eye mask – the medical device has a new design and is easier to use. The contents of the self-heating eye mask for the treatment of blepharitis (inflammation of the eyelid margins), meibomian gland dysfunction (blockage of the meibomian glands) as well as hordeolum and chalazion are now colourless instead of orange, and the metal plates required for activation are larger and have a red border. The medical device is part of the “concept for healthy eyelids” presented by URSAPHARM at the beginning of the year and and has been available since April 2024.
The self-heating POSIFORLID® eye mask with click mechanism enables simple and effective heat treatment for blepharitis, meibomian gland dysfunction and hordeolum or chalazion. Thanks to its relaxing and calming effect, it is also suitable for treating dry, tired or burning eyes. The contents of the mask, which is manufactured in Germany, are now colourless to make the metal plates more visible. After activating the click mechanism via the round metal plates, which now have a red border and are also larger, the previously colourless contents become milky. The new POSIFORLID® eye mask then gives off a constant heat of around 45 °C for 10 minutes. In combination with two moistened cotton pads, which are inserted into the openings provided at the top of the mask, a warm, moist climate is created in the eye area. This helps to soften crusts or deposits on the edge of the eyelid and to liquefy the accumulated secretion in the meibomian glands. By subsequently massaging the eyelids, the liquefied secretion can be removed from the sebaceous glands. The constant heat also promotes blood circulation to the eyelid margins. The heat treatment thus improves the function of the meibomian glands and should be carried out twice a day – in the morning and in the evening. The eyelids should then be cleaned and cared for – for example with the POSIFORLID® eye spray or the POSIFORLID® eyelid hygiene wipes from URSAPHARM’s “concept for healthy eyelids”. The POSIFORLID® eye mask can be reused up to 90 times.
The POSIFORLID® eye mask is part of the new “concept for healthy eyelids”
The new POSIFORLID® eye mask is part of the “concept for healthy eyelids”, which URSAPHARM presented at the beginning of 2024. The aim of the concept is to treat eyelid diseases such as blepharitis or meibomian gland dysfunction with various measures, thereby alleviating the symptoms of those affected and improving their quality of life and well-being. The individual therapy options are based on three stages: basic therapy, further pharmacological therapy and complementary therapy. In this way, patients can be treated comprehensively, individually and effectively depending on the severity of their illness.
Highest quality from URSAPHARM – made in Germany
URSAPHARM Arzneimittel GmbH is an internationally operating, medium-sized pharmaceutical company that has established as the market leader in Germany and one of the leading suppliers in Europe thanks to its broad and high-quality product range in the field of ophthalmology. Since its foundation in 1974, URSAPHARM has been a guarantor for the consistent transfer of innovative pharmaceutical concept into successful medicinal products and medical devices. One of the most successful developments of the company, which is celebrating its 50th anniversary this year, is the HYLO® product family with eye drops and ointment for moisturising the eyes. The product portfolio is rounded off by various preparations for general medicine in the form of film-coated tablets, capsules, granules, sprays and ointments. In addition, URSAPHARM provides its expertise in development, production, quality control and quality assurance as a high-performance contract manufacturer and co-operation partner worldwide. Headquartered in Saarbrücken, the company has subsidiaries in France, Benelux, Italy, Austria, Switzerland, Poland, the Czech Republic, Slovakia, Portugal, Russia and India as well as co-operation agreements with distribution partners in over 80 countries.
Press contact:
dot.communications
Tel: +49 (0)89/530797-23
ursapharm@dot-communications.de
